Prelude Capital Management’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
– Sell
-1,250
Closed -$287K – 1269
2015
Q4
$287K Hold
1,250
– – 0.04% 426
2015
Q3
$386K Sell
1,250
-188
-13% -$44.4K 0.06% 341
2015
Q2
$330K Buy
1,438
+1,300
+942% +$323K 0.05% 425
2015
Q1
$38K Buy
+138
New +$42.2K 0.01% 1476

Other funds holding BIS

Prelude Capital Management's BIS Position: Q1 2016 in Review

Prelude Capital Management sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2016, closing a stake of 1,250 shares — an estimated $287K sold.

Prelude Capital Management first reported a position in BIS in Q1 2015 and held it in 4 quarters. The position peaked at $386K in Q3 2015. 14 funds tracked by Wall St. Rank hold BIS as of Q1 2016.

  • Prelude Capital Management reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2016 after selling out during the quarter.
  • Prelude Capital Management sold 1,250 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2016, an estimated $287K.
  • Prelude Capital Management first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q1 2015 and held it in 4 quarters.
  • Prelude Capital Management's ProShares UltraShort NASDAQ Biotechnology position peaked at $386K in Q3 2015.
  • 14 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2016.

Based on Prelude Capital Management's 13F filing for Q1 2016, filed 16 May 2016.